Predictive Oncology Stock Buy Hold or Sell Recommendation
| POAI Stock | USD 0.78 0.02 2.50% |
Given the investment horizon of 90 days and complete risk avoidance on your part, our recommendation regarding Predictive Oncology is 'Strong Sell'. The recommendation algorithm takes into account all of Predictive Oncology's available fundamental, technical, and predictive indicators you will find on this site.
Check out Predictive Oncology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide. In addition, we conduct extensive research on individual companies such as Predictive and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Predictive |
Execute Predictive Oncology Buy or Sell Advice
The Predictive recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Predictive Oncology. Macroaxis does not own or have any residual interests in Predictive Oncology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Predictive Oncology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Predictive Oncology Trading Alerts and Improvement Suggestions
| Predictive Oncology generated a negative expected return over the last 90 days | |
| Predictive Oncology has high historical volatility and very poor performance | |
| Predictive Oncology has some characteristics of a very speculative penny stock | |
| Predictive Oncology has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.78 M. Net Loss for the year was (13.98 M) with profit before overhead, payroll, taxes, and interest of 1 M. | |
| Predictive Oncology currently holds about 25.39 M in cash with (13.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
| Predictive Oncology has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Chung-welch Nancy of 2675 shares of Predictive Oncology subject to Rule 16b-3 |
Predictive Oncology Returns Distribution Density
The distribution of Predictive Oncology's historical returns is an attempt to chart the uncertainty of Predictive Oncology's future price movements. The chart of the probability distribution of Predictive Oncology daily returns describes the distribution of returns around its average expected value. We use Predictive Oncology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Predictive Oncology returns is essential to provide solid investment advice for Predictive Oncology.
| Mean Return | -0.07 | Value At Risk | -8.64 | Potential Upside | 9.09 | Standard Deviation | 5.75 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Predictive Oncology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Predictive Stock Institutional Investors
| Shares | Advisor Group Holdings, Inc. | 2024-06-30 | 425 | Psi Advisors, Llc | 2024-09-30 | 399 | Bank Of America Corp | 2024-06-30 | 33.0 | Pfs Partners, Llc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 0.0 | Raymond James & Associates | 2024-06-30 | 0.0 | Jpmorgan Chase & Co | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 71.3 K | Geode Capital Management, Llc | 2024-09-30 | 51.9 K | Ubs Group Ag | 2024-06-30 | 35.6 K |
Predictive Oncology Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (11.3K) | 527.5K | 27.5M | (6.1M) | (13.3M) | (12.7M) | |
| Free Cash Flow | (8.8M) | (12.6M) | (13.2M) | (12.8M) | (13.5M) | (12.8M) | |
| Depreciation | 704.9K | 1.0M | 1.3M | 1.3M | 739.3K | 393.6K | |
| Other Non Cash Items | 8.1M | 13.8M | 1.2M | 11.2M | 452.8K | 430.2K | |
| Capital Expenditures | 26.6K | 360.8K | 962.3K | 475.7K | 302.4K | 199.3K | |
| Net Income | (19.4M) | (25.9M) | (19.7M) | (25.7M) | (14.0M) | (14.7M) | |
| End Period Cash Flow | 150.8K | 678.3K | 28.2M | 22.1M | 8.7M | 4.7M | |
| Change To Inventory | 91.1K | (94.7K) | (98.1K) | (42.8K) | (63.9K) | (60.7K) | |
| Investments | (599.1K) | (167.5K) | (10.6M) | (475.7K) | (373.3K) | (391.9K) | |
| Change To Netincome | 6.1M | 12.6M | 7.1M | 11.2M | 12.9M | 13.5M |
Predictive Oncology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Predictive Oncology or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Predictive Oncology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Predictive stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.3 | |
β | Beta against Dow Jones | 1.83 | |
σ | Overall volatility | 5.85 | |
Ir | Information ratio | -0.03 |
Predictive Oncology Volatility Alert
Predictive Oncology exhibits very low volatility with skewness of 0.91 and kurtosis of 2.17. Predictive Oncology is a potential penny stock. Although Predictive Oncology may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Predictive Oncology. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Predictive instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Predictive Oncology Fundamentals Vs Peers
Comparing Predictive Oncology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Predictive Oncology's direct or indirect competition across all of the common fundamentals between Predictive Oncology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Predictive Oncology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Predictive Oncology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Predictive Oncology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Predictive Oncology to competition |
| Fundamentals | Predictive Oncology | Peer Average |
| Return On Equity | -1.49 | -0.31 |
| Return On Asset | -0.56 | -0.14 |
| Operating Margin | (11.44) % | (5.51) % |
| Current Valuation | 4.5 M | 16.62 B |
| Shares Outstanding | 6.67 M | 571.82 M |
| Shares Owned By Insiders | 2.16 % | 10.09 % |
| Shares Owned By Institutions | 4.01 % | 39.21 % |
| Number Of Shares Shorted | 160.52 K | 4.71 M |
| Price To Book | 2.64 X | 9.51 X |
| Price To Sales | 2.96 X | 11.42 X |
| Revenue | 1.78 M | 9.43 B |
| Gross Profit | 1 M | 27.38 B |
| EBITDA | (13.18 M) | 3.9 B |
| Net Income | (13.98 M) | 570.98 M |
| Cash And Equivalents | 25.39 M | 2.7 B |
| Cash Per Share | 0.32 X | 5.01 X |
| Total Debt | 2.86 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 7.74 X | 2.16 X |
| Book Value Per Share | 2.04 X | 1.93 K |
| Cash Flow From Operations | (13.19 M) | 971.22 M |
| Short Ratio | 1.26 X | 4.00 X |
| Earnings Per Share | (2.96) X | 3.12 X |
| Target Price | 3.0 | |
| Number Of Employees | 34 | 18.84 K |
| Beta | 1.15 | -0.15 |
| Market Capitalization | 5.18 M | 19.03 B |
| Total Asset | 14.42 M | 29.47 B |
| Retained Earnings | (167.76 M) | 9.33 B |
| Working Capital | 6.13 M | 1.48 B |
| Net Asset | 14.42 M |
Note: Acquisition by Chung-welch Nancy of 2675 shares of Predictive Oncology subject to Rule 16b-3 [view details]
Predictive Oncology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Predictive . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Predictive Oncology Buy or Sell Advice
When is the right time to buy or sell Predictive Oncology? Buying financial instruments such as Predictive Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Predictive Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Dividend Beast Thematic Idea Now
Dividend Beast
An experimental equal-weighted theme of equities with high dividend yield and solid fundamentals based on Macroaxis rating system. The Dividend Beast theme has 69 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Dividend Beast Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Predictive Oncology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share 0.416 | Quarterly Revenue Growth (0.43) | Return On Assets (0.56) | Return On Equity (1.49) |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.